Vertex Pharmaceuticals Incorporated

Related records

Trials (287)

• 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
• A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
• A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis
• A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
• A Long-term Follow-up Study in Participants Who Received CTX001
• A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
• A Microneurography (MNG) Study of VX-150 in Healthy Participants
• A Microneurography Study of NaV1.8 Inhibition in Healthy Adults
• A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
• A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
• A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
• A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults
• A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants
• A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants
• A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants
• A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
• A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993
• A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C
• A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
• A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation